Abstract
Background A glycerol throat spray containing cold-adapted cod trypsin creates a protective barrier and is known to deactivate common cold virus in vitro and decrease pharyngeal rhinovirus load after inoculation in humans. Early self-diagnosis and use of the medical device ColdZyme indicate a safe alternative for treatment in naturally occurring common colds.
Methods This was a double-blind, randomized, parallel-group, placebo-controlled study conducted at ten German sites to evaluate the efficacy of the medical device ColdZyme, a glycerol mouth spray containing cold-adapted cod trypsin, for naturally occurring common cold, versus placebo. Adults experiencing a minimum of three common colds during the previous year, but otherwise healthy, were enrolled to begin treatment with the mouth spray or placebo six times daily at first sign of a common cold. Jackson’s symptom scale and the 9-item Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) quality of life (QoL) domain and sore throat scale were recorded daily by subjects, as well as any use of allowed rescue treatment. The trial is registered at ClinicalTrials.gov, number NCT03794804.
Results Between January and April 2019, 701 subjects were enrolled and randomly assigned to the ColdZyme group (n=351) or the placebo group (n=350). Of the 701 subjects, 438 (62.5%) subjects developed symptoms typical of common cold, and all 438 started study treatment (n=220 in the ColdZyme group and n=218 in the placebo group).
There were no differences between the groups in primary and major secondary endpoints, however, the assessment using the WURSS-21 QoL domain and Jackson score suggests a slightly faster recovery with ColdZyme, as symptoms and complaints affecting the quality of life were shortened about 1 day. The beneficial effect of ColdZyme was particularly noticeable on the fifth day of the common cold. A positive difference between treatment groups was also seen for the subjects’ assessments of global efficacy of the investigational product, and a robust safety profile for ColdZyme was demonstrated throughout the study.
Conclusion The safety and tolerability of ColdZyme have been confirmed in a larger study population, while establishing evidence of a slightly faster recovery from common cold symptoms.
Competing Interest Statement
F.L. was employed by Enzymatica AB when the study was conducted. F.L. has a patent pending. I.N is employed by Enzymatica AB. J.R. and D.R. have provided consultancy services and have received payment from Enzymatica AB for services rendered. J.R. was contracted as an independent statistical consultant by the sponsor. D.R. was contracted as a scientific advisor.
Clinical Trial
NCT03794804
Funding Statement
The trial was funded by Enzymatica AB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Four Ethics Committees (Ethikkommission der Charite, Berlin; Landesarztekammer Brandenburg, Cottbus; Sachsische Landesarztekammer, Dresden; and Landesarztekammer Baden-Wurttemberg, Stuttgart) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual participant data, after having been anonymized, will be made available, along with the study protocol, statistical analysis plan and informed consent form template. Data will be available beginning 3 months and ending 5 years after publication of the article to researchers whose proposed use of the data is approved by the study sponsor. Proposals should be directed to the corresponding author and requesters will need to sign a data access agreement.
